SEOUL, Samsung Biologics Co. on Wednesday reported its fourth-quarter net income of 290.7 billion won (US$217.4 million), down 21.4 percent from a year earlier. The company said in a regulatory filing that it posted 350 billion won in operating profit for the quarter, compared with 312.8 billion won a year ago. Revenue rose 11.2 percent to 1.07 trillion won. The operating profit was 10.5 percent higher than the average estimate, according to a survey by Yonhap Infomax, the financial data firm of Yonhap News Agency. The estimate of net profit was not available. Source: Yonhap News Agency